Brief: Kairos Pharma Enters Agreement with PreCheck Health Services
24/09/2024 21:27
Sept 24 (Reuters) - Kairos Pharma Ltd KAPA.A :
* KAIROS PHARMA ENTERS AGREEMENT WITH PRECHECK HEALTH
SERVICES TO
DEVELOP BIOMARKERS TO IDENTIFY PATIENTS RESPONSIVE TO ENV105 TO
TARGET CANCER DRUG RESISTANCE IN PROSTATE AND LUNG CANCER
PATIENTS
Source text for Eikon: ID:nGNX99x9bk
Further company coverage: KAPA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kairos Pharma
See all newsBrief: Kairos Pharma Announces Signing Of Binding Strategic Asset Acquisition Of Exclusive Worldwide Rights To Cl-273 From Orbimed And Torrey Pines Investment-Backed Celyn Therapeutics
Brief: Kairos Pharma Announces Signing Of Term Sheet For Strategic Asset Acquisition
Brief: Kairos Pharma To Present Positive Safety And Efficacy Data From Phase 2 Prostate Cancer Trial At Esmo 2025
Brief: Kairos Pharma Reports Positive Interim Phase 2 Data For ENV105 In Advanced Prostate Cancer, PFS Over One Year
Brief: Kairos Pharma Announces Virtual KOL Event To Provide Perspectives On ENV105 Interim Efficacy Results In Advanced Prostate Cancer